Damora Therapeutics, Inc. (NASDAQ: DMRA) Stock Competitors & Peer Comparison
See DMRA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DMRA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DMRA | $28.82 | -1.20% | 1.8B | -6.43 | -$4.48 | N/A |
| VRTX | $477.36 | +0.90% | 121.1B | 25.36 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $656.01 | +0.63% | 67.6B | 14.38 | $45.63 | +0.55% |
| ARGX | $918.22 | -0.69% | 57.1B | 82.87 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.50 | -0.31% | 41.8B | -2.29 | -$4.15 | N/A |
| RVMD | $189.23 | +0.25% | 40.2B | -26.77 | -$7.07 | N/A |
| ALNY | $271.77 | +1.13% | 36.3B | 48.97 | $5.55 | N/A |
| ONC | $325.90 | -0.27% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
DMRA vs VRTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while VRTX trades at $477.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas VRTX's P/E ratio is 25.36. In terms of profitability, DMRA's ROE is -1.23%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, DMRA is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
DMRA vs VRNA Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DMRA's ROE is -1.23%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, DMRA is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
DMRA vs REGN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, REGN has a market cap of 67.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while REGN trades at $656.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas REGN's P/E ratio is 14.38. In terms of profitability, DMRA's ROE is -1.23%, compared to REGN's ROE of +0.14%. Regarding short-term risk, DMRA is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
DMRA vs ARGX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ARGX has a market cap of 57.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ARGX trades at $918.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ARGX's P/E ratio is 82.87. In terms of profitability, DMRA's ROE is -1.23%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, DMRA is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
DMRA vs SGEN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DMRA's ROE is -1.23%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DMRA is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
DMRA vs RVMDW Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while RVMDW trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas RVMDW's P/E ratio is -2.29. In terms of profitability, DMRA's ROE is -1.23%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, DMRA is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
DMRA vs RVMD Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, RVMD has a market cap of 40.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while RVMD trades at $189.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas RVMD's P/E ratio is -26.77. In terms of profitability, DMRA's ROE is -1.23%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, DMRA is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check RVMD's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
DMRA vs ALNY Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ALNY has a market cap of 36.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ALNY trades at $271.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ALNY's P/E ratio is 48.97. In terms of profitability, DMRA's ROE is -1.23%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, DMRA is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
DMRA vs ONC Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ONC's P/E ratio is 72.91. In terms of profitability, DMRA's ROE is -1.23%, compared to ONC's ROE of +0.12%. Regarding short-term risk, DMRA is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
DMRA vs ROIV Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ROIV trades at $35.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ROIV's P/E ratio is -35.99. In terms of profitability, DMRA's ROE is -1.23%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, DMRA is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
DMRA vs INCY Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, INCY has a market cap of 23.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while INCY trades at $117.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas INCY's P/E ratio is 15.82. In terms of profitability, DMRA's ROE is -1.23%, compared to INCY's ROE of +0.29%. Regarding short-term risk, DMRA is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check INCY's competition here
Insmed Incorporated (NASDAQ: INSM)
DMRA vs INSM Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, INSM has a market cap of 23.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while INSM trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas INSM's P/E ratio is -18.59. In terms of profitability, DMRA's ROE is -1.23%, compared to INSM's ROE of -1.30%. Regarding short-term risk, DMRA is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check INSM's competition here
BioNTech SE (NASDAQ: BNTX)
DMRA vs BNTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, BNTX has a market cap of 22.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while BNTX trades at $89.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas BNTX's P/E ratio is -19.34. In terms of profitability, DMRA's ROE is -1.23%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, DMRA is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
DMRA vs UTHR Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while UTHR trades at $528.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas UTHR's P/E ratio is 19.51. In terms of profitability, DMRA's ROE is -1.23%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DMRA is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
DMRA vs MRNA Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, MRNA has a market cap of 21.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while MRNA trades at $54.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas MRNA's P/E ratio is -6.63. In terms of profitability, DMRA's ROE is -1.23%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, DMRA is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
DMRA vs BGNE Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DMRA's ROE is -1.23%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, DMRA is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
DMRA vs DNA-WT Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.23%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, DMRA is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
DMRA vs GMAB Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas GMAB's P/E ratio is 20.77. In terms of profitability, DMRA's ROE is -1.23%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, DMRA is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
DMRA vs NBIX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while NBIX trades at $175.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas NBIX's P/E ratio is 25.40. In terms of profitability, DMRA's ROE is -1.23%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, DMRA is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check NBIX's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
DMRA vs BBIO Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while BBIO trades at $84.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas BBIO's P/E ratio is -22.47. In terms of profitability, DMRA's ROE is -1.23%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, DMRA is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
DMRA vs JAZZ Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while JAZZ trades at $253.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas JAZZ's P/E ratio is 19.74. In terms of profitability, DMRA's ROE is -1.23%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, DMRA is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
DMRA vs ASND Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ASND has a market cap of 15.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ASND trades at $253.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ASND's P/E ratio is -104.90. In terms of profitability, DMRA's ROE is -1.23%, compared to ASND's ROE of -56.42%. Regarding short-term risk, DMRA is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
DMRA vs EXEL Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, EXEL has a market cap of 13.9B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while EXEL trades at $55.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas EXEL's P/E ratio is 16.58. In terms of profitability, DMRA's ROE is -1.23%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, DMRA is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
DMRA vs KRTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DMRA's ROE is -1.23%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DMRA is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check KRTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
DMRA vs MDGL Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while MDGL trades at $544.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas MDGL's P/E ratio is -42.54. In terms of profitability, DMRA's ROE is -1.23%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, DMRA is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check MDGL's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
DMRA vs AXSM Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while AXSM trades at $241.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas AXSM's P/E ratio is -62.92. In terms of profitability, DMRA's ROE is -1.23%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, DMRA is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
DMRA vs ARWR Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ARWR has a market cap of 12.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ARWR trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ARWR's P/E ratio is -39.81. In terms of profitability, DMRA's ROE is -1.23%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, DMRA is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
DMRA vs BMRN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, BMRN has a market cap of 11.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while BMRN trades at $59.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas BMRN's P/E ratio is 28.52. In terms of profitability, DMRA's ROE is -1.23%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, DMRA is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
DMRA vs RNAM Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DMRA's ROE is -1.23%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, DMRA is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
DMRA vs TECH Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while TECH trades at $71.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas TECH's P/E ratio is 36.91. In terms of profitability, DMRA's ROE is -1.23%, compared to TECH's ROE of +0.05%. Regarding short-term risk, DMRA is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check TECH's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
DMRA vs SMMT Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, SMMT has a market cap of 10.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while SMMT trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas SMMT's P/E ratio is -8.54. In terms of profitability, DMRA's ROE is -1.23%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, DMRA is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
DMRA vs CYTK Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CYTK trades at $80.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CYTK's P/E ratio is -13.85. In terms of profitability, DMRA's ROE is -1.23%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, DMRA is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CYTK's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
DMRA vs KRYS Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while KRYS trades at $335.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas KRYS's P/E ratio is 44.81. In terms of profitability, DMRA's ROE is -1.23%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, DMRA is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
DMRA vs HALO Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while HALO trades at $81.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas HALO's P/E ratio is 17.73. In terms of profitability, DMRA's ROE is -1.23%, compared to HALO's ROE of +1.26%. Regarding short-term risk, DMRA is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
DMRA vs RXDX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DMRA's ROE is -1.23%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DMRA is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check RXDX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
DMRA vs IONS Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, IONS has a market cap of 9.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while IONS trades at $56.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas IONS's P/E ratio is -32.88. In terms of profitability, DMRA's ROE is -1.23%, compared to IONS's ROE of -0.59%. Regarding short-term risk, DMRA is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check IONS's competition here
Abivax S.A. (NASDAQ: ABVX)
DMRA vs ABVX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ABVX trades at $125.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ABVX's P/E ratio is -65.89. In terms of profitability, DMRA's ROE is -1.23%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, DMRA is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
DMRA vs NUVL Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas NUVL's P/E ratio is -21.79. In terms of profitability, DMRA's ROE is -1.23%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, DMRA is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
DMRA vs KYMR Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while KYMR trades at $110.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas KYMR's P/E ratio is -31.32. In terms of profitability, DMRA's ROE is -1.23%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, DMRA is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
DMRA vs CRNX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CRNX trades at $83.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CRNX's P/E ratio is -16.32. In terms of profitability, DMRA's ROE is -1.23%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, DMRA is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CRNX's competition here
Alkermes plc (NASDAQ: ALKS)
DMRA vs ALKS Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ALKS trades at $52.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ALKS's P/E ratio is 55.67. In terms of profitability, DMRA's ROE is -1.23%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, DMRA is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ALKS's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
DMRA vs PTGX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while PTGX trades at $136.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas PTGX's P/E ratio is -75.20. In terms of profitability, DMRA's ROE is -1.23%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, DMRA is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
DMRA vs IMGN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DMRA's ROE is -1.23%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DMRA is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
DMRA vs TGTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, TGTX has a market cap of 8.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while TGTX trades at $56.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas TGTX's P/E ratio is 19.26. In terms of profitability, DMRA's ROE is -1.23%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, DMRA is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
DMRA vs BPMC Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DMRA's ROE is -1.23%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, DMRA is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
DMRA vs APGE Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas APGE's P/E ratio is -31.01. In terms of profitability, DMRA's ROE is -1.23%, compared to APGE's ROE of -0.33%. Regarding short-term risk, DMRA is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
DMRA vs CERE Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CERE's P/E ratio is -16.47. In terms of profitability, DMRA's ROE is -1.23%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DMRA is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CERE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
DMRA vs IMVT Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while IMVT trades at $39.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas IMVT's P/E ratio is -14.76. In terms of profitability, DMRA's ROE is -1.23%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, DMRA is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
DMRA vs PCVX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while PCVX trades at $54.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas PCVX's P/E ratio is -7.94. In terms of profitability, DMRA's ROE is -1.23%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, DMRA is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
DMRA vs IBRX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, IBRX has a market cap of 7.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while IBRX trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas IBRX's P/E ratio is -8.35. In terms of profitability, DMRA's ROE is -1.23%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, DMRA is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
DMRA vs MTSR Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DMRA's ROE is -1.23%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, DMRA is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check MTSR's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
DMRA vs RYTM Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, RYTM has a market cap of 7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while RYTM trades at $102.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas RYTM's P/E ratio is -32.62. In terms of profitability, DMRA's ROE is -1.23%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, DMRA is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check RYTM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
DMRA vs PRAX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while PRAX trades at $325.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas PRAX's P/E ratio is -24.33. In terms of profitability, DMRA's ROE is -1.23%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, DMRA is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check PRAX's competition here
Merus N.V. (NASDAQ: MRUS)
DMRA vs MRUS Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DMRA's ROE is -1.23%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, DMRA is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check MRUS's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
DMRA vs COGT Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while COGT trades at $39.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas COGT's P/E ratio is -18.84. In terms of profitability, DMRA's ROE is -1.23%, compared to COGT's ROE of -0.83%. Regarding short-term risk, DMRA is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check COGT's competition here
Arcellx, Inc. (NASDAQ: ACLX)
DMRA vs ACLX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ACLX's P/E ratio is -28.27. In terms of profitability, DMRA's ROE is -1.23%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, DMRA is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ACLX's competition here
Erasca, Inc. (NASDAQ: ERAS)
DMRA vs ERAS Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ERAS trades at $19.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ERAS's P/E ratio is -20.55. In terms of profitability, DMRA's ROE is -1.23%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, DMRA is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ERAS's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
DMRA vs RETA Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas RETA's P/E ratio is -66.29. In terms of profitability, DMRA's ROE is -1.23%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DMRA is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check RETA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
DMRA vs PTCT Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, PTCT has a market cap of 6.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while PTCT trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas PTCT's P/E ratio is -32.97. In terms of profitability, DMRA's ROE is -1.23%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, DMRA is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
DMRA vs CNTA Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CNTA's P/E ratio is -22.63. In terms of profitability, DMRA's ROE is -1.23%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, DMRA is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CNTA's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
DMRA vs SYRE Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, SYRE has a market cap of 6.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while SYRE trades at $102.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas SYRE's P/E ratio is -49.10. In terms of profitability, DMRA's ROE is -1.23%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, DMRA is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check SYRE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
DMRA vs BLTE Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while BLTE trades at $153.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas BLTE's P/E ratio is -82.01. In terms of profitability, DMRA's ROE is -1.23%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, DMRA is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check BLTE's competition here
CG Oncology Inc. (NASDAQ: CGON)
DMRA vs CGON Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CGON trades at $69.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CGON's P/E ratio is -29.75. In terms of profitability, DMRA's ROE is -1.23%, compared to CGON's ROE of -0.23%. Regarding short-term risk, DMRA is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CGON's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
DMRA vs LGND Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while LGND trades at $300.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas LGND's P/E ratio is 36.03. In terms of profitability, DMRA's ROE is -1.23%, compared to LGND's ROE of +0.16%. Regarding short-term risk, DMRA is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
DMRA vs SRRK Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while SRRK trades at $47.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas SRRK's P/E ratio is -13.28. In terms of profitability, DMRA's ROE is -1.23%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, DMRA is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check SRRK's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
DMRA vs MIRM Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, MIRM has a market cap of 5.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while MIRM trades at $113.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas MIRM's P/E ratio is -8.30. In terms of profitability, DMRA's ROE is -1.23%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, DMRA is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check MIRM's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
DMRA vs CDTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DMRA's ROE is -1.23%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, DMRA is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
DMRA vs ABCM Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DMRA's ROE is -1.23%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DMRA is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
DMRA vs ISEE Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DMRA's ROE is -1.23%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DMRA is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
DMRA vs TVTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while TVTX trades at $57.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas TVTX's P/E ratio is -260.73. In terms of profitability, DMRA's ROE is -1.23%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, DMRA is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
DMRA vs APLS Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas APLS's P/E ratio is 38.35. In terms of profitability, DMRA's ROE is -1.23%, compared to APLS's ROE of +0.40%. Regarding short-term risk, DMRA is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check APLS's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
DMRA vs XENE Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, XENE has a market cap of 5.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while XENE trades at $65.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas XENE's P/E ratio is -13.92. In terms of profitability, DMRA's ROE is -1.23%, compared to XENE's ROE of -0.49%. Regarding short-term risk, DMRA is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check XENE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
DMRA vs TERN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas TERN's P/E ratio is -51.41. In terms of profitability, DMRA's ROE is -1.23%, compared to TERN's ROE of -0.20%. Regarding short-term risk, DMRA is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
DMRA vs DFTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while DFTX trades at $43.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas DFTX's P/E ratio is N/A. In terms of profitability, DMRA's ROE is -1.23%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, DMRA is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
DMRA vs MANE Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, MANE has a market cap of 4.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while MANE trades at $109.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas MANE's P/E ratio is -34.92. In terms of profitability, DMRA's ROE is -1.23%, compared to MANE's ROE of -0.84%. Regarding short-term risk, DMRA is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
DMRA vs FOLD Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas FOLD's P/E ratio is -161.00. In terms of profitability, DMRA's ROE is -1.23%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, DMRA is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
DMRA vs AKRO Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DMRA's ROE is -1.23%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, DMRA is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check AKRO's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
DMRA vs CRSP Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CRSP trades at $46.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CRSP's P/E ratio is -9.11. In terms of profitability, DMRA's ROE is -1.23%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, DMRA is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CRSP's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
DMRA vs ALPN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DMRA's ROE is -1.23%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DMRA is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ALPN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
DMRA vs EWTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while EWTX trades at $40.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas EWTX's P/E ratio is -24.60. In terms of profitability, DMRA's ROE is -1.23%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, DMRA is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check EWTX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
DMRA vs CAI Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CAI trades at $15.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CAI's P/E ratio is -85.37. In terms of profitability, DMRA's ROE is -1.23%, compared to CAI's ROE of +0.06%. Regarding short-term risk, DMRA is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
DMRA vs DNTH Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, DNTH has a market cap of 4.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while DNTH trades at $103.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas DNTH's P/E ratio is -25.15. In terms of profitability, DMRA's ROE is -1.23%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, DMRA is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
DMRA vs ACAD Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ACAD trades at $24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ACAD's P/E ratio is 12.18. In terms of profitability, DMRA's ROE is -1.23%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, DMRA is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ACAD's competition here
Opthea Limited (NASDAQ: OPT)
DMRA vs OPT Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas OPT's P/E ratio is -1.52. In terms of profitability, DMRA's ROE is -1.23%, compared to OPT's ROE of +1.18%. Regarding short-term risk, DMRA is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
DMRA vs MRTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DMRA's ROE is -1.23%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DMRA is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
DMRA vs LEGN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while LEGN trades at $22.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas LEGN's P/E ratio is -32.68. In terms of profitability, DMRA's ROE is -1.23%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, DMRA is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check LEGN's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
DMRA vs DYN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, DYN has a market cap of 4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while DYN trades at $24.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas DYN's P/E ratio is -7.59. In terms of profitability, DMRA's ROE is -1.23%, compared to DYN's ROE of -0.58%. Regarding short-term risk, DMRA is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check DYN's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
DMRA vs VKTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while VKTX trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas VKTX's P/E ratio is -8.40. In terms of profitability, DMRA's ROE is -1.23%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, DMRA is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
DMRA vs CELC Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CELC has a market cap of 4B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CELC trades at $82.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CELC's P/E ratio is -21.18. In terms of profitability, DMRA's ROE is -1.23%, compared to CELC's ROE of -2.45%. Regarding short-term risk, DMRA is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
DMRA vs CPRX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CPRX's P/E ratio is 12.30. In terms of profitability, DMRA's ROE is -1.23%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DMRA is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
DMRA vs ELVN Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ELVN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ELVN's P/E ratio is -31.71. In terms of profitability, DMRA's ROE is -1.23%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, DMRA is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
DMRA vs RYZB Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DMRA's ROE is -1.23%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DMRA is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
DMRA vs CBAY Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DMRA's ROE is -1.23%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DMRA is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check CBAY's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
DMRA vs DNLI Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while DNLI trades at $23.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas DNLI's P/E ratio is -8.02. In terms of profitability, DMRA's ROE is -1.23%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, DMRA is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check DNLI's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
DMRA vs NAMSW Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas NAMSW's P/E ratio is -10.50. In terms of profitability, DMRA's ROE is -1.23%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, DMRA is less volatile compared to NAMSW. This indicates lower risk in terms of short-term price fluctuations for DMRA.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
DMRA vs ADPT Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while ADPT trades at $22.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas ADPT's P/E ratio is -41.24. In terms of profitability, DMRA's ROE is -1.23%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, DMRA is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check ADPT's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
DMRA vs SWTX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas SWTX's P/E ratio is -13.78. In terms of profitability, DMRA's ROE is -1.23%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, DMRA is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
DMRA vs NAMS Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while NAMS trades at $29.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas NAMS's P/E ratio is -18.64. In terms of profitability, DMRA's ROE is -1.23%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, DMRA is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check NAMS's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
DMRA vs TLX Comparison July 2026
Damora Therapeutics, Inc. (NASDAQ: DMRA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMRA stands at 1.8B. In comparison, TLX has a market cap of 3.5B. Regarding current trading prices, DMRA is priced at $28.82 on the NASDAQ, while TLX trades at $10.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMRA currently has a P/E ratio of -6.43, whereas TLX's P/E ratio is -555.43. In terms of profitability, DMRA's ROE is -1.23%, compared to TLX's ROE of -0.02%. Regarding short-term risk, DMRA is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for DMRA.Check TLX's competition here